Clinical AI Product Management: What Transfers and What Breaks

Search for "clinical AI product manager" and almost every result is a job posting. The postings I read ask for product experience, clinical workflow knowledge, regulatory familiarity and some understanding of machine learning, but none of them explains how the job differs from product work on a consumer AI app. I have worked on both sides of that gap, though not in one job. I was an Associate Product Manager at ImagineArt on ChatlyAI, a consumer AI chat product, and then an AI researcher at the University of Alberta, building and evaluating clinical prediction models. This essay is my map of what carries over from consumer AI product work to clinical AI, what breaks, and what I would check before a clinical AI feature goes on a roadmap.

A caveat up front. I have not been the product manager on a clinical product. What follows comes from doing consumer AI product work and clinical ML research, and from thinking about where the two meet. Where I'm giving an opinion, I say so.

What carries over from consumer AI product work

More transfers than the job postings suggest. The core of an AI PM's job, as I described in AI product manager vs. product manager, is writing down what a good output looks like before anyone builds. That skill matters even more in clinical work.

Four habits from ChatlyAI I would bring unchanged:

• Defining quality before scope. A spec for a model-powered feature has to say which outputs are good, which are bad, and which bad ones are unacceptable. In a clinical setting the unacceptable list gets longer and more specific, but the exercise is the same.
• Instrumenting what users actually do. At ImagineArt I implemented end-to-end event tracking from Google Tag Manager into Mixpanel, with real-time dashboards. Any clinical tool needs the same visibility into whether people use the output, ignore it or override it.
• Reading feedback at volume. I synthesized 3,000+ user feedback points a month into product decisions. The habit of reading complaints as evidence about where a model fails carries over directly.
• Working across functions. I worked across engineering, design, SEO, branding, support and QA. A clinical product adds clinicians, compliance and data governance to that list. The coordination skill is the same; the stakes of a missed handoff are higher.

What doesn't carry over is the feedback loop, and that changes almost everything else.

What breaks: the cost of a wrong answer

On a consumer chat product, a bad answer usually costs a retry. The user rephrases, gets a better answer, or leaves. Each of those shows up in your data. Retention, regeneration rates and complaints tell you, fairly quickly, where the model is failing. The ChatlyAI growth from 200K to 1.2M+ monthly active users came through feature prioritization and growth experiments, and that kind of fast experimentation depends on mistakes being cheap and visible.

In my view, clinical AI flips both properties. A wrong output can be expensive, because it may feed into a decision about a patient. And it can be invisible, because a clinician who trusts a wrong prediction doesn't file a complaint. They act on it. Nothing in your event stream tells you the output was wrong, and the outcome that would tell you may arrive months later, if it is recorded at all.

In consumer AI, users report the model's mistakes. In clinical AI, you have to find them before anyone relies on them.

That has three consequences for the product manager. You can't rely on post-launch metrics to find quality problems, so evaluation has to happen before launch and carry more weight. You can't treat "ship and iterate" as the default plan for model behavior. And you have to design for the clinician who disagrees with the model, not only the one who agrees.

Evaluation becomes a product requirement

On a consumer product, offline evaluation is mostly the engineering team's concern. In clinical AI I think the product manager has to understand it well enough to read a results table and ask the right questions, because the evaluation is the main evidence that the feature works.

The research taught me which questions those are. My evaluation work at the University of Alberta relied on patient-level bootstrap confidence intervals, DeLong testing, leakage audits, patient-disjoint evaluation and seed-noise analysis. Each one maps to a question a PM can ask without writing code:

• Patient-disjoint evaluation. "Could the same patient appear in both training and test data?" If yes, the test score is likely to be optimistic.
• Leakage audits. "Could any input contain information recorded after the moment the prediction is supposed to be made?" A clinical note written after a diagnosis can quietly give the answer away.
• Confidence intervals. "How wide is the uncertainty around this number?" A single score without an interval is a claim nobody can check.
• Comparison tests. "Is model B really better than model A, or within noise?" I wrote up the method in DeLong test in Python, including why resampling rows instead of patients makes weak results look significant.
• Seed noise. "If we retrain with a different random seed, how much does the score move?" A gap smaller than that movement isn't a finding.

None of these questions needs a statistics degree, and none appears in a typical consumer AI spec. In my opinion, a clinical AI PM who can't ask them has to take the model team's word for whether the product works.

Some outcomes have ceilings

This is the part of clinical ML research I find most useful for product decisions. In the multimodal work, combining ECG waveforms with clinical text substantially improved cardiovascular outcome prediction. For rare stroke and bleeding outcomes, the results pointed to information ceilings: the inputs carry only so much signal about the outcome, and a better architecture can't add signal that isn't there. I developed and evaluated 8 multimodal fusion architectures in that work, and I describe the trade-offs between them in early vs. late fusion in clinical ML.

For a product manager, a ceiling is a scoping decision. If the available data cannot predict an outcome well, no model iteration will fix it, and the honest roadmap says so. Sometimes that means choosing a different outcome, adding a data source, or not building the feature. In consumer AI you can often paper over a weak model with product design. I don't think you can do that in clinical AI, because the weak output still reaches a decision.

The multimodal finding also matters for product design. If a model works best with both an ECG and a clinical note, the product has to handle the patient who has only one of them. Which inputs are reliably available at the moment of the prediction is a product question, and it should be answered before modeling starts.

Data rules and regulation shape the roadmap

My research used MIMIC-IV, which means credentialed access through PhysioNet and rules about what can be shared. That is why this essay contains no performance numbers from that work: unpublished results stay unpublished. A clinical product team lives with the same kind of constraint every day. Access to data, and what you are allowed to do with it, decides your timeline before any model is trained.

Regulation is the other constraint, and the one I'm least qualified to summarize. I haven't shipped a regulated medical product, so I won't paraphrase rules here. What I would do as a PM is put one question to a regulatory specialist before the roadmap hardens: given what this feature is intended to do, which requirements apply? In my view the answer changes what you can ship, what you must document and how fast you can change the model afterwards, so it belongs at the start of planning, not the end. The job postings that ask for "regulatory familiarity" are asking for that instinct: know which questions to route, and route them early.

Trust: the clinician is both the user and the auditor

On ChatlyAI, a user who distrusted an answer could ask again. A clinician who distrusts an output usually ignores the tool, and a tool that is ignored is the same as one that doesn't exist. In why most AI products fail in year one I argue that putting AI at the wrong moment in a workflow kills products. In a clinical setting I'd expect that effect to be stronger, because a clinician's time is the scarcest resource in the room.

In my opinion, three design choices earn trust:

• Show uncertainty honestly. A prediction with a stated confidence is more useful than a confident-looking score that hides how often it is wrong.
• Make overrides easy and record them. Overrides are the closest thing clinical AI has to the consumer "regenerate" button. They are your best signal that the model is failing a group of patients.
• Fit the existing workflow. A tool that needs a separate screen or extra typing competes with patient care for attention, and it will lose.

Consumer AI vs. clinical AI, side by side

A checklist before a clinical AI feature goes on the roadmap

These are the questions I would want answered, in writing, before committing to a clinical AI feature:

1. What decision does this output inform, and who makes it?
2. What is the cost of a false positive, and of a false negative, for that decision?
3. Which inputs are reliably available at the moment of prediction, and what happens when one is missing?
4. Was the model evaluated on patients it never saw in training, with confidence intervals?
5. Has someone audited the inputs for information recorded after the prediction time?
6. Is there evidence the outcome is predictable from this data, or are we near a ceiling?
7. Which regulatory and data-use requirements apply, according to someone qualified to say?
8. How will we see overrides and outcomes after launch, and who reviews them?

If a team can't answer questions 4 to 6, I'd treat the feature as a research project rather than a roadmap item. That is less exciting than a launch date, but it is the honest status. The product and research roles this essay draws on are listed under experience.